Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019.

Autor:	Tesema E; Challenge TB/KNCV TB Foundation, Addis Ababa, Ethiopia., Wares F; Challenge TB/KNCV TB Foundation, The Hague, The Netherlands., Bedru A; Challenge TB/KNCV TB Foundation, Addis Ababa, Ethiopia., Negeri C; Challenge TB/KNCV TB Foundation, Addis Ababa, Ethiopia., Molla Y; Challenge TB/KNCV TB Foundation, Addis Ababa, Ethiopia., Gemechu D; Challenge TB/MSH, Addis Ababa, Ethiopia., Kassa A; ABT Associates, Federal Ministry of Health, Addis Ababa, Ethiopia., Tsegaye F; ALERT Hospital, Addis Ababa, Ethiopia., Taye L; National TB Programme, Federal Ministry of Health, Addis Ababa, Ethiopia.
Jazyk:	angličtina
Zdroj:	Public health action [Public Health Action] 2021 Jun 21; Vol. 11 (2), pp. 50-52.
DOI:	10.5588/pha.20.0065
Abstrakt:	Background: Drug-resistant TB (DR-TB) remains a major public health concern. DR-TB patient data from ALERT (All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre) Hospital, Addis Ababa, Ethiopia, who received bedaquiline (BDQ) and/or delamanid (DLM) containing regimens were analysed. Results: From 2017 to 2019, 51 DR-TB patients were enrolled. Of 33 patients, 31 (93.9%) had culture converted at 6 months. Of those with final outcomes, 77% ( n = 10) were cured. Thirty (58.8%) developed adverse events, the most frequent of which were gastrointestinal disorders (70%), haematological disorders (16.7%) and QTc prolongation (16.7%). Twenty patients discontinued the offending drug permanently. Conclusion: With close monitoring, introduction of new DR-TB regimens brought good early results, which encouraged wider programmatic implementation in Ethiopia. Competing Interests: Conflict of interests: none declared. (© 2021 The Union.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu